FlandersBio talked about Novosanis receiving the Seal of Excellence for the Uroscreen project
You are here
The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee in cervical screening programs. Colli-Pee is designed to collect the first-void urine in a non-invasive way. First-void urine can be used for detecting human papillomavirus (HPV) which can cause cervical cancer.
An international panel of independent experts evaluated the UROSCREEN proposal on 4 different criteria: excellence, impact, quality and efficiency of implementation. The panel decided to grant a “Seal of Excellence” and labeled UROSCREEN as an innovative project proposal. This recognition underlines the potential of Colli-Pee in enabling a more efficient screening program on HPV by offering a non-invasive self-sampling device initially to non-attendees of the screening programs. Novosanis submitted the project proposal UROSCREEN to Horizon 2020 in the area of clinical research for the validation of diagnostic medical devices.
Dr. Vanessa Vankerckhoven, CEO of Novosanis, commented: “We are delighted with the recognition by Horizon 2020 and hope this brings more attention to the full potential of Colli-Pee in the screening of patients, especially non-attendees of the screening programs, across Europe.”
About Colli-Pee
Colli-Pee™ efficiently captures first-void urine (first part of the urine stream). Collection of first-void urine allows for improved detection of sexually transmitted infections (STIs), including Chlamydia, gonorrhea and Human Papillomavirus (HPV), a virus that can cause cervical cancer, as well as cancer biomarkers (prostate and bladder). Colli-Pee™ is a user-friendly and compact device that is suited for postal delivery. Both men and women can use it. The Colli-Pee™ device platform allows for collection of different pre-defined volumes for a range of medical applications.
About Horizon 2020
Horizon 2020 is the biggest EU Research and Innovation program between 2014-2020, offering nearly €80 billion in funding. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.